Japan Long-term Safety for Tiotropium Plus Olodaterol

Summary

The primary objective of this study is to assess the safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT Inhaler) in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start

2012-02

Primary completion

2013-09

Completion

2013-09

Drugs

Indications